How to Fight Insurance Denials for Maternity and Postpartum Care

This guide covers denials for prenatal screening (NIPT and first-trimester combined screening), maternal-fetal medicine consults, breast pumps, lactation consultant visits, doula services, medications for nausea and hyperemesis gravidarum (Diclegis, Bonjesta, Zofran), compounded 17-hydroxyprogesterone caproate (17-OHP) for preterm birth prevention, GBS prophylaxis, RhoGAM, pregnancy vaccines (Tdap, influenza, COVID-19, and Abrysvo for maternal RSV), and postpartum mental health treatment including Zurzuvae for postpartum depression. Denials in this space are common because the Affordable Care Act (ACA) mandates zero-cost-sharing preventive services for pregnant and postpartum patients, yet insurers routinely impose restrictions that contradict professional society guidelines — age cutoffs for NIPT, "medical necessity" reviews for lactation support, step therapy for hyperemesis drugs, and experimental/investigational labels for newer postpartum treatments. When federal law, ACOG Practice Bulletins, SMFM Consults, ACIP vaccine schedules, and HRSA Women's Preventive Services Guidelines all say one thing and your denial letter says another, you have grounds for a successful appeal.

Why Insurers Deny Maternity and Postpartum Care

1. Age or risk-tier cutoffs for NIPT (cell-free DNA prenatal screening)

The most common template: "Non-invasive prenatal testing is only covered for advanced maternal age (≥35 at delivery) or when you have a documented high-risk indication such as abnormal ultrasound, family history of aneuploidy, or positive first-trimester screen. Your request does not meet criteria." Many plans cite internal medical policies requiring "high-risk pregnancy" even though ACOG, ACMG, and SMFM now recommend offering cfDNA screening to all pregnant patients regardless of age.

2. "Not medically necessary" for breast pumps, lactation consultants, or doula services

Denial language: "The requested double-electric breast pump / IBCLC visit / doula service is not medically necessary because you have not documented insufficient milk supply / latch failure / medical complication." This directly conflicts with ACA §2713 and the HRSA Women's Preventive Services Guidelines, which list comprehensive lactation support and breastfeeding supplies—including breast pumps—as preventive services that all non-grandfathered plans must cover at zero cost-sharing, without a diagnosis or failed first-line therapy.

3. Step therapy or "experimental/investigational" labels for hyperemesis and postpartum mental health drugs

For Diclegis/Bonjesta (the only FDA-approved drugs for nausea and vomiting of pregnancy): "Brand-name Diclegis is not covered; you must try over-the-counter doxylamine plus pyridoxine purchased separately." For off-label Zofran in severe hyperemesis: "Ondansetron is not FDA-approved for pregnancy; consider non-pharmacologic measures." For Zurzuvae (zuranolone), the first oral drug approved for postpartum depression: "This is experimental; try sertraline or another SSRI first."

4. "Withdrawn from market" or "compounded drug not covered" for 17-OHP

After the branded product Makena was voluntarily withdrawn in April 2023, many insurers stopped covering compounded 17-hydroxyprogesterone caproate injections, citing the withdrawal or a blanket "compounded drugs excluded" clause. But SMFM released a statement in October 2023 affirming that patients with a documented prior spontaneous preterm birth should still have access to compounded 17-OHP, because no FDA-approved alternative exists and the evidence still supports use in that specific population.

5. Timing, frequency, or scope restrictions on vaccines, RhoGAM, and postpartum follow-up

Examples: "Abrysvo maternal RSV vaccine is not a covered preventive service; it is too new." "RhoGAM at 28 weeks requires documented anti-D titer first." "Postpartum depression screening is bundled into the global maternity fee; a separate postpartum mental health visit is not separately reimbursable." ACIP vaccine schedules, CDC/ACOG guidance on Rh immunoglobulin, and the ACA preventive-services mandate all directly refute these.

---

The Citations Insurers Respect

When you appeal, naming the right guideline—with the year and, when applicable, the update or reaffirmation—makes the difference between a form-letter denial and approval. Here are the references that carry weight in maternity appeals:

NIPT and Prenatal Screening

• ACOG Practice Bulletin No. 226 (September 2020): "Screening for Fetal Chromosomal Abnormalities" — states that cell-free DNA screening should be discussed and offered to all pregnant patients, regardless of maternal age or a priori risk.
• ACMG Professional Statement (2023 update): Endorses cfDNA as a primary screening option for all pregnancies.
• SMFM Consult Series #50 (2016), reaffirmed 2021: Supports cfDNA for all pregnancies; no age restriction.
• NEXT trial, New England Journal of Medicine (2015): Demonstrated superior performance of cfDNA compared to combined first-trimester screening.

Breast Pumps, Lactation, and Doula Services

• ACA §2713 (enacted March 2010): Requires non-grandfathered plans to cover, without cost-sharing, all women's preventive services as outlined by HRSA.
• HRSA Women's Preventive Services Guidelines (2021 update): Lists "comprehensive lactation support and counseling by a trained provider" and "costs of renting breastfeeding equipment" (i.e., breast pumps) as covered preventive services.
• AAP/ACOG Breastfeeding Handbook for Physicians (3rd ed., 2023): Underscores the clinical role of IBCLCs in all breastfeeding dyads, not just those with documented problems.
• State Medicaid doula coverage: As of 2024, Illinois, New York, Oregon, Rhode Island, New Jersey, Minnesota, Virginia, Maryland, Nevada, Massachusetts, and the District of Columbia have passed laws requiring Medicaid managed-care plans to cover doula services; private plans in those states are beginning to follow suit under parity principles.

Hyperemesis Gravidarum (HG) and Nausea/Vomiting of Pregnancy (NVP)

• ACOG Practice Bulletin No. 189 (January 2018, reaffirmed 2022): "Nausea and Vomiting of Pregnancy" — lists doxylamine/pyridoxine (Diclegis, Bonjesta) as first-line pharmacotherapy when dietary modification fails; mentions ondansetron as an option for refractory cases despite off-label use.
• FDA Approval of Diclegis (2013) and Bonjesta (2018): These are the only FDA-approved drugs specifically for NVP; demanding "try OTC separately" contradicts the labeled indication.

17-Hydroxyprogesterone Caproate (17-OHP) for Preterm Birth Prevention

• SMFM Statement (October 2023): After Makena withdrawal, SMFM reaffirmed that patients with a documented prior spontaneous preterm birth <37 weeks should still be offered compounded 17-OHP, because it remains the only progesterone formulation studied in this population and PROLONG trial (2019) data do not override individual shared decision-making.
• ACOG Practice Bulletin No. 234 (May 2021, reaffirmed 2023): "Prediction and Prevention of Spontaneous Preterm Birth" — supports 17-OHP for singleton pregnancies with prior spontaneous PTB.

Vaccines in Pregnancy

• CDC/ACIP Immunization Schedules (updated annually): Recommend Tdap during each pregnancy (ideally 27–36 weeks), annual influenza vaccine, COVID-19 vaccination, and (as of August 2023) maternal RSV vaccine (Abrysvo) between 32–36 weeks' gestation.
• FDA Approval of Abrysvo for Maternal Immunization (August 2023): First RSV vaccine approved to protect infants via maternal antibody transfer.
• ACOG Committee Opinion on Immunization During Pregnancy (periodically updated): States that all ACIP-recommended vaccines in pregnancy are preventive services under ACA §2713.

RhoGAM (Rh Immunoglobulin)

• ACOG Practice Bulletin No. 181 (August 2017, reaffirmed 2021): "Prevention of Rh D Alloimmunization" — standard of care is 300 mcg Rh immunoglobulin at 28 weeks for Rh-negative patients, plus within 72 hours post-delivery if the infant is Rh-positive; no pre-authorization titer required.

Postpartum Mental Health

• ACOG Committee Opinion No. 757 (November 2018, reaffirmed 2022): "Screening for Perinatal Depression" — recommends at least one full depression screen during the perinatal period using a validated tool (EPDS, PHQ-9).
• FDA Approval of Zurzuvae (zuranolone) (August 2023): First oral drug specifically indicated for postpartum depression; 14-day course.
• ACA §2713 + HRSA Guidelines: Postpartum depression screening is a covered preventive service with no cost-sharing.

---

How to Argue Against Each Major Denial Reason

1. "NIPT Only Covered If You're ≥35 or High-Risk"

Step 1: Cite ACOG Practice Bulletin No. 226 (September 2020), which explicitly states that cell-free DNA screening "should be discussed with and offered to all pregnant patients, regardless of maternal age or baseline risk."

Step 2: Reference the ACMG 2023 update and SMFM Consult #50 (reaffirmed 2021), both of which removed age thresholds.

Step 3: Explain the clinical rationale: the NEXT trial (NEJM 2015) showed cfDNA has a higher detection rate and lower false-positive rate than combined first-trimester screening for trisomy 21, 18, and 13 across all risk categories. Restricting NIPT to "high-risk" patients means lower-risk patients get an inferior screening test, which contradicts the standard of care.

Step 4: If your plan's own policy still lists an age cutoff, argue that the policy is outdated and inconsistent with current evidence-based guidelines. Many insurers update their medical policies only every 2–3 years; you can request the policy review date and point out that the major society guidelines have changed.

Step 5: If you already paid out-of-pocket for NIPT, file a simultaneous claim for reimbursement, citing the same bulletins, and request that the plan update its policy prospectively for all members.

2. "Breast Pump / Lactation Consultant / Doula Not Medically Necessary"

Step 1: Invoke ACA §2713 by name: "The Affordable Care Act requires that all non-grandfathered plans cover, without cost-sharing, the preventive services listed in the HRSA Women's Preventive Services Guidelines."

Step 2: Quote the HRSA Guidelines (2021): "Comprehensive lactation support and counseling by a trained provider during the antenatal and postpartum periods" and "costs of renting breastfeeding equipment (breast pumps)" are required preventive services. No diagnosis, no "medical necessity" threshold, no prior authorization.

Step 3: If the plan argues you haven't documented a breastfeeding problem, respond that the ACA preventive mandate is prophylactic—it covers services to prevent problems, not only to treat them. Analogy: health plans cover annual well-woman visits and mammograms before you have a cancer diagnosis; the same principle applies to lactation.

Step 4: For doula services, cite your state's Medicaid coverage law if applicable (Illinois, New York, Oregon, Rhode Island, New Jersey, Minnesota, Virginia, Maryland, Nevada, Massachusetts, DC as of 2024) and argue parity: if the state Medicaid program recognizes doulas as cost-effective and evidence-based, a commercial plan's blanket denial is inconsistent with public health policy and the emerging standard of care.

Step 5: Attach a letter of medical necessity from your OB or midwife (even a short one) noting that lactation support and a breast pump are part of your postpartum care plan. Many plans will approve once a clinician co-signs, even though the law doesn't require it.

3. Step Therapy or "Experimental" Labels for Hyperemesis and Postpartum Depression Drugs

For Diclegis / Bonjesta:

Step 1: Cite ACOG Practice Bulletin No. 189 (January 2018, reaffirmed 2022), which lists doxylamine/pyridoxine combination as first-line pharmacotherapy for nausea and vomiting of pregnancy when nonpharmacologic measures are insufficient.

Step 2: Emphasize that Diclegis (2013) and Bonjesta (2018) are the only FDA-approved drugs for this indication. Requiring you to purchase OTC doxylamine and pyridoxine separately and combine them yourself means you are not receiving the FDA-approved formulation; compliance and dosing accuracy suffer, and the plan is effectively denying you access to the labeled drug.

Step 3: If the plan still insists on a trial of separate OTC components first, document that trial clearly—dates, doses, and outcome (e.g., "Pyridoxine 25 mg TID + doxylamine 25 mg at bedtime for 14 days → persistent vomiting 4–6 episodes/day, weight loss 3 lb, ketonuria 2+")—then resubmit for the branded product as second-line.

For Zofran (Ondansetron) in Refractory HG:

Step 4: Cite the same ACOG Bulletin No. 189, which acknowledges that ondansetron is commonly used off-label for refractory cases of hyperemesis gravidarum and has the most robust evidence among antiemetics, despite the lack of an FDA pregnancy indication.

Step 5: Provide documentation of severity: weight loss >5%, ketonuria, prior emergency department visits or IV hydration, failure of doxylamine/pyridoxine and metoclopramide. Off-label use is the standard of care when the condition is severe and FDA-approved alternatives have failed.

For Zurzuvae (Zuranolone) for Postpartum Depression:

Step 6: Cite the FDA approval (August 2023) for postpartum depression and any forthcoming ACOG guidance. As the first oral drug specifically indicated for PPD (versus brexanolone, which requires 60-hour IV infusion), zuranolone fills a treatment gap.

Step 7: Argue that demanding an SSRI trial first is step therapy applied to a novel mechanism (GABA-A modulator, 14-day course) that is not interchangeable with SSRIs. If you have already tried or cannot tolerate SSRIs, document that. The FDA approved zuranolone on the strength of SKYLARK and ROBIN trials showing rapid symptom improvement; denying it in favor of weeks-long SSRI titration delays effective treatment during a critical postpartum window.

4. "Compounded 17-OHP Not Covered After Makena Withdrawal"

Step 1: Cite the SMFM Statement (October 2023): "For patients with a documented prior spontaneous preterm birth, SMFM continues to support shared decision-making regarding use of compounded 17-OHP, as it remains the only progesterone preparation studied in this population."

Step 2: Reference ACOG Practice Bulletin No. 234 (May 2021, reaffirmed 2023), which still lists 17-OHP as an intervention to reduce recurrent preterm birth in singletons with prior spontaneous PTB <37 weeks.

Step 3: Explain that Makena was withdrawn because a post-approval confirmatory trial (PROLONG, 2019) did not demonstrate efficacy in a broad, more heterogeneous population; but SMFM and ACOG have not withdrawn the recommendation for the original FDA-approved indication (prior spontaneous PTB). The compounded formulation is bioequivalent to the branded product that was initially approved; your case fits the original indication.

Step 4: If the plan's policy says "compounded drugs are excluded," argue that this blanket exclusion cannot override medically necessary treatment when no FDA-approved alternative exists. Request an exception to policy, and cite your state's insurance regulations if they require coverage of compounded drugs when a commercially available equivalent is unavailable.

Step 5: Have your MFM or OB write a detailed letter of medical necessity documenting your prior preterm birth (gestational age, spontaneous vs. indicated), current singleton gestation, and the absence of any contraindications to 17-OHP.

5. Timing, Frequency, or Scope Restrictions on Vaccines, RhoGAM, and Postpartum Follow-Up

For Maternal RSV Vaccine (Abrysvo):

Step 1: Cite the FDA approval (August 2023) and the CDC/ACIP recommendation that Abrysvo be offered to pregnant individuals at 32–36 weeks' gestation to protect their infants from RSV in the first six months of life.

Step 2: Invoke ACA §2713: ACIP-recommended vaccines are preventive services that must be covered without cost-sharing. Abrysvo is now on the ACIP schedule; the fact that it is "new" does not exempt the plan from the ACA mandate. (In fact, ACA §2713 requires plans to cover new ACIP recommendations within one plan year.)

Step 3: If the plan says "we are still reviewing the vaccine," note that the law does not provide a multi-year grace period; plans must incorporate ACIP updates for the plan year beginning one year after the recommendation is issued.

For RhoGAM:

Step 4: Cite ACOG Practice Bulletin No. 181 (August 2017, reaffirmed 2021), which sets the standard protocol: Rh immunoglobulin 300 mcg at 28 weeks for all Rh-negative unsensitized patients, no pre-authorization antibody screen required at that visit (the screen happens earlier in pregnancy, typically at the first prenatal visit).

Step 5: If the insurer demands a 28-week titer before approving RhoGAM, explain that this is not the standard of care and adds unnecessary cost and delay. The whole point of the 28-week dose is prophylaxis before any sensitization event.

For Postpartum Depression Screening and Treatment:

Step 6: Cite ACOG Committee Opinion No. 757 (November 2018, reaffirmed 2022) and the HRSA Women's Preventive Services Guidelines, which include postpartum depression screening.

Step 7: If the insurer says screening and follow-up are "bundled" into the global maternity fee, argue that the ACA preventive mandate requires zero cost-sharing. If your plan charges you a copay or applies the visit to your deductible, that violates §2713. Request a refund of any cost-sharing and prospective correction.

Step 8: For treatment after a positive screen (EPDS ≥10, PHQ-9 ≥10), document the score and timeline. If your OB refers you to psychiatry or prescribes zuranolone or an SSRI, those are not "preventive" (they're treatment), but they must still be covered as medically necessary under any standard maternal mental health benefit; denial on the grounds of "not related to pregnancy" is incorrect, because postpartum depression is by definition a pregnancy-related condition.

---

What We Do

We turn these citations, trial names, and regulatory sections into a structured, persuasive appeal letter that meets your plan's procedural requirements and deadline. We draft the clinical narrative, pull the relevant journal articles and policy statements, cite your state's insurance laws when they strengthen the case, and deliver a final document you can submit directly or hand to your OB to submit on your behalf. Maternity and postpartum denials are especially time-sensitive—pregnancy advances by the week, and postpartum mental health crises do not wait for a 60-day review—so we prioritize rapid turnaround and, when needed, expedited/urgent appeal language.

---

Sources

1. Affordable Care Act §2713, 42 U.S.C. § 300gg-13 (2010).

2. Health Resources & Services Administration (HRSA), Women's Preventive Services Guidelines (2021 update).

3. American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 226, "Screening for Fetal Chromosomal Abnormalities," Obstetrics & Gynecology 136, no. 3 (September 2020): e48–e69. Reaffirmed 2023.

4. American College of Medical Genetics and Genomics (ACMG), "Noninvasive Prenatal Screening for Fetal Aneuploidy, 2023 Update," Genetics in Medicine (2023).

5. Society for Maternal-Fetal Medicine (SMFM) Consult Series #50, "The Use of Cell-Free DNA for Aneuploidy Screening," (2016, reaffirmed 2021).

6. Norton ME, Jacobsson B, Swamy GK, et al., "Cell-free DNA Analysis for Noninvasive Examination of Trisomy (NEXT)," New England Journal of Medicine 372 (2015): 1589–97.

7. ACOG Practice Bulletin No. 189, "Nausea and Vomiting of Pregnancy," Obstetrics & Gynecology 131, no. 1 (January 2018): e15–e30. Reaffirmed 2022.

8. U.S. Food and Drug Administration, Approval of Diclegis (doxylamine/pyridoxine) NDA 021876 (April 2013); Approval of Bonjesta NDA 208533 (September 2018).

9. Society for Maternal-Fetal Medicine (SMFM), Statement on Compounded 17-Hydroxyprogesterone Caproate (October 2023).

10. ACOG Practice Bulletin No. 234, "Prediction and Prevention of Spontaneous Preterm Birth," Obstetrics & Gynecology 137, no. 5 (May 2021): e65–e90. Reaffirmed 2023.

11. Blackwell SC, Gyamfi-Bannerman C, et al., "17-OHPC to Prevent Recurrent Preterm Birth: PROLONG Trial," American Journal of Obstetrics & Gynecology 221, no. 2 (2019): 142.e1–142.e18.

12. Centers for Disease Control and Prevention (CDC) / Advisory Committee on Immunization Practices (ACIP), Immunization Schedules (updated annually). Maternal RSV vaccine (Abrysvo) recommendation added August 2023.

13. U.S. Food and Drug Administration, Approval of Abrysvo (RSVpreF) for Maternal Immunization, BLA 125769 (August 2023).

14. ACOG Practice Bulletin No. 181, "Prevention of Rh D Alloimmunization," Obstetrics & Gynecology 130, no. 2 (August 2017): e57–e70. Reaffirmed 2021.

15. ACOG Committee Opinion No. 757, "Screening for Perinatal Depression," Obstetrics & Gynecology 132, no. 5 (November 2018): e208–e212. Reaffirmed 2022.

16. U.S. Food and Drug Administration, Approval of Zurzuvae (zuranolone) NDA 217639 (August 4, 2023), for postpartum depression.

17. Deligiannidis KM, Meltzer-Brody S, et al., "Zuranolone for the Treatment of Postpartum Depression (SKYLARK and ROBIN studies)," American Journal of Psychiatry 180, no. 9 (2023): 668–75.

18. American Academy of Pediatrics (AAP) / ACOG, Breastfeeding Handbook for Physicians, 3rd ed. (2023).

19. State Medicaid Doula Coverage: Illinois (HB158, eff. March 2023), New York (eff. 2019), Oregon (HB2359, eff. 2014), Rhode Island, New Jersey, Minnesota, Virginia, Maryland, Nevada, Massachusetts, District of Columbia (various effective dates 2019–2024).